Abiopharma

🔍 Guyer William (Executive)

Company: CORCEPT THERAPEUTICS INC (CORT)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock at $21.65 per share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: false | shares_owned_after: 25,487.00 | transaction_form_type: 4
• Sold 15,594 shares of Common Stock at $70.392 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 9,893.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,406 shares of Common Stock at $70.8478 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 5,487.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 20,000 shares of Stock option (right to buy) at $21.65 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2031-09-01 | equity_swap_involved: false | shares_owned_after: 330,000.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
• F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.725 to $70.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.725 to $71.08 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F4: Fully exercisable.
• REMARKS: The power of attorney under which this form was signed is on file with the Commission.